(thirdQuint)Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML).

 This study is a randomized, open-label, parallel-arm, fixed-dose, standard therapy controlled Phase IIB trial.

 Study enrollment duration is expected to be approximately 12-18 months.

 On entry, patients are randomized to receive either CPX-351 or intensive first salvage treatment.

 Patients are stratified to balance the likelihood of obtaining a CR and the duration of CR between the two arms.

.

 Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)@highlight

The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.

 The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.

